Please assess the completion status of the following clinical trial:

Trial Title: Effect of Raloxifene Plus Cholecalciferol and Cholecalciferol Alone on the Bone Mineral Density in Postmenopausal Women With Osteopenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Postmenopausal women (defined as no menstruation for more than 48 weeks prior to screening and no other pathological or physiological causes. If in doubt, a serum follicle-stimulating hormone (FSH) test may be performed at screening)~2. Osteopenia ( -2.5 SD\< T-score \< -1.0 SD in DXA )~Exclusion Criteria:~1. Secondary osteoporosis (Systemic glucocorticoid use, aromatase inhibitor, thyrotoxicosis, hypeparathyroidism, etc)~2. Vitamin D deficiency at baseline (25-OH-vitD \<10ng/mL)~3. Active cancer treatment~4. History of vascular thrombosis~5. Bisphosphonate treatment within the last 12months~6. Contraindication for Raloxifene according to the SPC

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Raloxifen plus cholecalciferol (Type: ACTIVE_COMPARATOR): Raloxifene 60mg + Cholecalciferol 800 IU
- Cholecalciferol (Type: ACTIVE_COMPARATOR): Cholecalciferol 800 IU

Based on this trial design, predict the completion outcome and termination type (if applicable).